07:46 AM EDT, 03/24/2025 (MT Newswires) -- GSK (GSK) said Monday the European Medicines Agency accepted for review its application to expand the use of Nucala to include maintenance treatment of chronic obstructive pulmonary disease with an eosinophilic phenotype.

The application for the treatment, also known as mepolizumab, was backed by results from a phase 3 trial that showed a "statistically significant and clinically meaningful reduction" in the annualized rate of moderate or severe exacerbations with mepolizumab, compared with a placebo, the UK pharma giant said.

Chronic obstructive pulmonary disease is an inflammatory lung disease that can include chronic bronchitis and/or emphysema.